NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer indications AMSTERDAM, (GLOBE NEWSWIRE) -- Avidicure, a biotechnology ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

The trial enrolled patients with NSCLC that had PD-L1 expression on ... “Imfinzi has helped change the treatment landscape and achieved multiple positive phase 3 trials for patients with earlier ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Qudian Inc. ("Qudian" or "the Company" or "We") , a consumer-oriented technology company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with ...

CGI will release results for its second quarter fiscal year 2025, ended March 31, 2025, on Wednesday, April 30, 2025 before the markets open. Management will host a conference call to discuss results ...